Invicta Diagnostic, a rapidly expanding diagnostic services provider operating under the brand name ‘PC Diagnostics’, has secured ₹60 million in a successful pre-IPO funding round. The round was led by Grobiz SME Opportunities Fund, along with several prominent angel investors, valuing the company at ₹600 million based on a 6.5x EBITDA multiple.
Socradamus Capital served as the advisor and sole Book Running Lead Manager for the upcoming IPO.
With a strong presence in the Mumbai Metropolitan Region, Invicta offers a full range of pathology and radiology testing services, including clinical laboratory diagnostics, imaging, and tele-radiology. The company currently operates through a network of seven diagnostic centres and one centralized laboratory.
As of May 31, 2025, Invicta provides over 60 routine and 487 specialized pathology tests, along with 96 basic and 130 advanced radiology tests. Its operations are structured around a hub-and-spoke model, which enables seamless sample collection and efficient diagnostic workflows through a centralized infrastructure.
The flagship centre in Thane serves as the primary hub, fully equipped to handle both pathology specimen collection and advanced radiology diagnostics. In addition, Invicta’s network includes three subsidiary-run hub centres, three spoke centres, and one central laboratory that is co-located with a spoke unit to maximize efficiency.
Invicta is promoted by an experienced team of healthcare professionals:
Dr. Ketan Jayantilal Jain, a radiologist with more than 15 years of clinical experience,
Dr. Sanket Jain, Chairman and Non-Executive Director, and
Rohit Srivastava, CFO, who brings over 20 years of investment banking and healthcare sector expertise.
The fresh capital infusion marks a pivotal moment in Invicta’s growth trajectory, enabling the company to scale its operations and deepen its integrated diagnostic offerings across urban and semi-urban areas of Maharashtra.
This strategic funding round positions Invicta for a robust IPO journey, as it continues to focus on expanding access to high-quality, comprehensive diagnostic services.